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Pneumonia Due to Staphylococcus aureus
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Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USAc; Duke
Clinical Research Institute, Durham, North Carolina, USAd; Menzies School of Health Research, Darwin, Northern Territory, Australiae
The impact of Panton-Valentine leukocidin (PVL) on the outcome in Staphylococcus aureus pneumonia is controversial. We
genotyped S. aureus isolates from patients with hospital-acquired pneumonia (HAP) enrolled in two registrational multina-
tional clinical trials for the genetic elements carrying pvl and 30 other virulence genes. A total of 287 isolates (173 methicillin-
resistant S. aureus [MRSA] and 114 methicillin-susceptible S. aureus [MSSA] isolates) from patients from 127 centers in 34
countries for whom clinical outcomes of cure or failure were available underwent genotyping. Of these, pvlwas detected by PCR
and its product confirmed in 23 isolates (8.0%) (MRSA, 18/173 isolates [10.4%]; MSSA, 5/114 isolates [4.4%]). The presence of
pvlwas not associated with a higher risk for clinical failure (4/23 [17.4%] versus 48/264 [18.2%]; P 1.00) or mortality. These
findings persisted after adjustment for multiple potential confounding variables. No significant associations between clinical
outcome and (i) presence of any of the 30 other virulence genes tested, (ii) presence of specific bacterial clone, (iii) levels of alpha-
hemolysin, or (iv) delta-hemolysin production were identified. This study suggests that neither pvl presence nor in vitro level of
alpha-hemolysin production is the primary determinant of outcome among patients with HAP caused by S. aureus.
The Panton-Valentine leukocidin (PVL) is a bacteriophage-associated, bicomponent cytotoxin produced by some strains
of Staphylococcus aureus. PVL induces host cell necrosis and apop-
tosis by producing pores in the cell membranes of neutrophils and
other infected cells. The presence of PVL and the genetic elements
coding for its production (two contiguous, cotranscribed genes,
lukS and lukF, here referred to as pvl) has been strongly associated
with a severe necrotizing pneumonia (13, 15). Although contro-
versy persists, there is evidence that PVL is associated with severe
disease in community-acquired pneumonia (CAP) due to S. au-
reus both in clinical reports (13, 15) and in some (10, 22), but not
all (3, 20, 30, 49), in vivomodel systems. However, the studies on
the association between PVL and clinical outcomes in hospital-
acquired pneumonia (HAP), a distinct clinical entity from CAP,
are limited.
Hospital-acquired pneumonia is the leading cause of morbid-
ity and mortality from nosocomial infections (9), and S. aureus is
the leading cause of HAP in U.S. hospitals (12, 28, 34). In the
current study, we tested the hypothesis that pvl presence in S.
aureus isolates causing HAP was associated with a worse clinical
outcome than the outcome of HAP caused by pvl-negative S. au-
reus counterparts. To test this hypothesis, we made use of a large
international cohort of S. aureus isolates from patients with HAP.
These isolates were collected in two identically designed phase III
clinical trials for S. aureusHAP.
MATERIALS AND METHODS
Patients and study settings. The ATTAIN (Assessment of Telavancin for
Hospital-Acquired Pneumonia) clinical trials were two identical phase III,
randomized, double-blinded, parallel-group, multinational trials (Clini-
calTrials.gov identifiers NCT00107952 and NCT00124020) studying the
efficacy and safety of intravenous telavancin versus vancomycin for the
treatment of hospital-acquired pneumonia (HAP) with a focus on pa-
tients with infections due to methicillin-resistant S. aureus (MRSA) (35).
Following randomization, patients were treated for 7 to 21 days with the
study drug. From January 2005 to June 2007, a total of 1,503 patients were
enrolled from 235 clinical centers in 38 countries. Patients were included
in the current study if all of the following criteria weremet: (i) inclusion in
the modified all treated (MAT) population (n  1,089), (ii) had mono-
microbial infection with S. aureus at baseline, and (iii) had a clinical re-
sponse of either “cure” or “failure” for the test-of-cure analysis. All pa-
tients or their legal guardian provided written informed consent. This
study was approved by Duke University Medical Center Institutional Re-
view Board.
Clinical outcomes and definitions. Clinical outcomes were estab-
lished by site investigators. Outcomes were defined as either “cure” or
“failure.” Cure was defined as (i) signs and symptoms of pneumonia im-
proved to the point that no further antibiotics for pneumonia are required
and (ii) baseline radiographic findings improved or did not progress.
Failure was defined as (i) persistence or progression of signs and symp-
toms of pneumonia that still require antibiotic therapy within two calen-
dar days of therapy with a potentially effective antistaphylococcal medi-
cation and/or (ii) death on or after day three attributable to primary
infection. TheMAT subgroup comprises all subjects who received at least
one dose of study medication and who had a baseline respiratory patho-
gen identified from respiratory samples or blood cultures if no respiratory
sample was positive.
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PCR assays for genotyping. S. aureus genomic DNA was extracted as
described previously (5), using an ultraclean microbial DNA kit (Mo Bio
Laboratories, Inc., Carlsbad, CA) in accordance with the manufacturer’s
instructions. PCR assays were used to screen the S. aureus genome for 31
putative bacterial virulence determinants, including adhesin genes (fnbA,
fnbB, clfA, clfB, cna, spa, sdrC, sdrD, sdrE, bbp, ebpS, andmap-eap), toxin
genes (pvl, eta, etb, tst, sea, seb, sec, sed, see, seg, seh, sei, and hlg), agr groups
I to IV, staphylococcal cassette chromosomemec element (SCCmec) types
I to IV, and other virulence genes (efb, icaA, chp, and the V8 protease
gene). The primers and PCR conditions used to amplify the genes of
interest were used as described previously (1, 5).
PVL Western blotting. S. aureus isolates were cultured overnight
from low-passage frozen stocks in CCY medium (3% [wt/vol] yeast
extract, 2% Bacto-Casamino Acids, 2.3% sodium pyruvate, 0.63%
Na2HPO4, and 0.041%KH2PO4, pH 6.7). Culture supernatants were pre-
pared from bacteria at the early or late stationary phase of growth as
described previously (17). LukF-PV and LukS-PV present in CCY culture
supernatants were detected byWestern blotting (immunoblotting) as de-
scribed by Graves et al. (17), except polyvinylidene difluoride (PVDF)
membranes were used with the iBlot dry blotting system (Invitrogen,
Carlsbad, California). The presence or absence of PVL subunits in S. au-
reus isolates was confirmed by two separate experiments. Quantitation of
immunoblots from both experiments was performed using an Alpha In-
notech gel documentation system (FluorChemFC2; Alpha Innotech
Corp., San Leandro, CA) and AlphaView software version 3.0.3.
MLST. Multilocus sequence typing (MLST) was performed as de-
scribed by Enright et al. (11). Sequences were analyzed in Seqman Pro
(DNA STAR Inc., Madison, WI) and compared with those in the public
database (www.mlst.net) to generate the sequence types (STs). STs were
grouped into clonal complexes (CCs) by using eBURST analysis tools at
http://eburst.mlst.net.
Alpha-hemolysin activity assay. Alpha-hemolysin activity was mea-
sured by quantitative analysis of rabbit red blood cell (RBC) hemolysis as
described earlier (19, 42) with the following slight modifications. Ten
milliliters of tryptic soy broth (TSB) (Becton Dickinson, Sparks, MD) in a
50-ml falcon tube was inoculated with a loopful of culture from a fresh
plate of each strain and incubated at 37°C/220 rpm for overnight culture.
An appropriate amount of overnight culture was inoculated into 10 ml of
Mueller-Hinton broth 2 (Sigma, St. Louis, MO) in a 50-ml falcon tube to
normalize the starting OD600 to 0.1 (107 CFU/ml) and incubated at
37°C/220 rpm for 20 h. After 20 h of incubation, the culture was spun
down at 4°C/3,100 rpm for 10min to remove the pellets. The supernatant
was then filter sterilized, transferred to a sterile tube, and stored at80°C
until further use.
The ability of the culture supernatant to lyse rabbit erythrocytes
(RBCs) was tested in a 96-well format. To do this, 100 l of 1:5-diluted
culture supernatant (in 1 phosphate-buffered saline [PBS]) of each
strain was loaded into the first well and then serially diluted up to 1:80 in
duplicate. After the dilution of each sample, 100 l of 1% rabbit RBCs
(Innovative Research, Novi, MI) in 1 PBS was added to each well and
incubated at 37°C for 1 h. Following incubation, plates were centrifuged
for 5 min, 100 l of the supernatant was removed gently to a new micro-
titer plate, and absorbance was read at 550 nm. Hemolytic units (HU) per
milliliter of alpha-hemolysin were defined as the inverse of the dilution
causing 50% of hemolysis. Sterile distilled water served as the 100% he-
molysis control (positive control), and 1 PBS was a negative control. All
experiments were performed in triplicate and the results averaged. Mean
alpha-hemolysin levels were defined as high if they were 10 hemolytic
units (HU)/ml and low if they were 10 HU/ml. To ensure that no bias
was introduced with this stratification, we repeated the analyses using cut
points of 5 HU/ml and 7 HU/ml. No differences in the overall findings
were introduced by varying the biological cut point definitions.
Delta-hemolysin activity assay. A delta-hemolysin activity assay was
performed to exclude the possibility of agrdysfunction as a potential cause
of clinical outcome. Delta-hemolysin activity on sheep blood agar plates
was determined as previously described (36). Briefly, on each sheep blood
agar plate, the beta-hemolysin-producing strain S. aureus RN4220 was
streaked vertically and test strains were streaked horizontally. After
overnight incubation at 37°C, the plates were observed for the enhanced
zone of hemolysis created by the interaction of the beta-hemolysin of
RN4420 and the delta-hemolysin of the test strain. S. aureus NRS149
(RN6607), also named 502A (standard agr group II prototype, obtained
from the Network on Antimicrobial Resistance in Staphylococcus aureus
[NARSA]), and S. aureus NRS 155 (RN9120, agr-null derivative of
RN6607) were used as positive and negative controls, respectively.
Statistical methods. The goal of this study was to investigate associa-
tions between clinical outcome of patients with S. aureus HAP and the
presence of pvl in the infecting strain. To accomplish this goal, genetically
defined patient subgroups (i.e., pvl-positive versus pvl-negative subjects)
were assessedwith the two-sample t test for continuously distributed vari-
ables, Fisher’s exact test for binomial variables, and the Fisher-Freeman-
Halton test for more general categorical variables (Table 1).
The association between clinical outcome and pvl status was assessed,
adjusting for potential confounding variables (Table 2).Multiple analyses
were conducted, and each stratified on a different covariate. Exact meth-
ods were used to test the null hypothesis that the odds ratio equaled unity
in all strata (that is, that therewas no association between clinical outcome
and pvl status), stratifying on the third variable.
The association between clinical outcome at test-of-cure and the pres-
ence/absence of each of a number of putative virulence genes (Table 3)
was assessed using Fisher’s exact test to test the null hypothesis of no
association.
Due to small sample sizes, the association between clinical outcome at
test-of-cure and the amount of alpha-lysin produced (10 HU/ml versus
10 HU/ml) (Table 4) was tested, with the MRSA and MSSA strains
pooled. Within PVL-positive and PVL-negative pathogens separately, an
exact stratified Cochran-Mantel-Haenzel test was conducted via Monte
Carlo simulation, stratifying on methicillin susceptibility (MRSA or
MSSA). All reported P values are two-sided. No adjustments were made
for multiple comparisons.
Results were obtained using SAS 9.2 (TS2M3) (SAS Institute Inc.,
Cary, NC) run on aWindows-based server. When exact results could not
be obtained fromSAS procedures, theywere obtainedwith either StatXact
9 PROCS run within the SAS environment or StatXact-8 run within Cytel
Studio 8 (both from the Cytel Software Corporation, Cambridge, MA).
RESULTS
Study population and baseline characteristics. Out of 1,503 pa-
tients enrolled in the ATTAIN studies, 287 patients from 127 cen-
ters in 34 countries met inclusion criteria for the current investi-
gation. Bacterial isolates were available for all 287 patients. Of the
287 isolates, 173 (60.3%) were MRSA and 114 (39.7%) were
MSSA. Baseline demographic characteristics of these patients are
outlined in Table 1.
Clinical characteristics and outcome according to pvl pres-
ence. Of the 287 isolates, 23 (8.0%) were positive for pvl (MRSA,
18/173 isolates [10.4%]; MSSA, 5/114 isolates [4.4%]). PVL pro-
tein was confirmed in all 23 isolates byWestern blotting of culture
supernatants (data not shown). No significant differences were
identified in clinical characteristics of patients infected with pvl-
positive and pvl-negative S. aureuswith the exception of higher pvl
prevalence in MRSA populations from North America (Table 1).
Next, we compared the outcomes of patients according to
presence of pvl. No significant differences were identified in the
clinical outcomes of patients with pvl-positive and pvl-negative S.
aureusHAP, either overall (cure rates were 19/23 [82.6%] for pvl-
positive cases versus 216/264 [81.8%] for pvl-negative cases; P
1.00) or within methicillin susceptibility subgroups (for MRSA,
PVL in S. aureus Hospital-Acquired Pneumonia
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16/18 [88.9%] for pvl-positive cases versus 123/155 [79.4%] for
pvl-negative cases [P  0.532]; for MSSA, 3/5 [60.0%] for pvl-
positive cases versus 93/109 [85.3%] for pvl-negative cases [P 
0.176]) (Fig. 1). There was also no significant difference in mor-
tality rates among the pvl-positive and pvl-negative groups (data
not shown). These findings persisted after adjustment for a num-
ber of potentially confounding clinical characteristics (Table 2).
To look for possible correlation between the amounts of PVL pro-
duction and clinical outcome, we next quantified the levels of
LukS and LukF components of PVL in all 23 pvl-positive isolates.
There was no difference in clinical outcome with the amount of
PVL production (data not shown).
Clinical outcome of HAP according to presence of other vir-
ulence genes.Next, we considered potential associations between
TABLE 1 Baseline characteristics of the study population according to the pvl gene status of the infecting pathogen among patients with hospital-
acquired pneumonia
Parameter
Value by PVL statusa
MRSA MSSA
Total
(n 173)
pvl negative
(n 155)
pvl positive
(n 18) P value
Total
(n 114)
pvl negative
(n 109)
pvl positive
(n 5) P value
Demographic characteristics
Mean age (SD) (yr)b 66.3 (15.91) 66.7 (15.40) 63.1 (20.04) 0.364 56.4 (19.79) 56.4 (20.21) 56.4 (6.43) 0.996
Male sexc 93 (53.8) 80 (51.65) 13 (72.2) 0.134 66 (57.9) 63 (57.8) 3 (60.0) 1.000
Region of enrollmentc
Europe 48 (27.7) 45 (29.0) 3 (16.7) 0.005 50 (43.9) 49 (45.0) 1 (20.0) 0.519
North America 46 (26.6) 35 (22.6) 11 (61.1) 27 (23.7) 25 (22.9) 2 (40.0)
Otherd 79 (45.7) 75 (48.4) 4 (22.2) 37 (32.5) 35 (32.1) 2 (40.0)
Prior antimicrobial therapyc 127 (73.4) 116 (74.8) 11 (61.1) 0.259 46 (40.4) 42 (38.5) 4 (80.0) 0.156
MRSA risk factorsc
Hospitalization within previous 6 months 109 (63.0) 100 (64.5) 9 (50.0) 0.302 41 (36.0) 40 (36.7) 1 (20.0) 0.653
Antibiotic treatment within prior 3 months 118 (68.2) 108 (69.7) 10 (55.6) 0.285 37 (32.5) 36 (33.0) 1 (20.0) 1.000
Chronic illness 144 (83.2) 130 (83.9) 14 (77.8) 0.509 67 (58.8) 63 (57.8) 4 (80.0) 0.647
Prior infection with MRSA 19 (11.0) 17 (11.0) 2 (11.1) 1.000 2 (1.8) 2 (1.8) 0 1.000
Admission from a nursing home or long term
care facility
34 (19.7) 30 (19.4) 4 (22.2) 0.757 10 (8.8) 10 (9.2) 0 1.000
Surgical procedure during current hospital stay 46 (26.6) 42 (27.1) 4 (22.2) 0.784 45 (39.5) 44 (40.4) 1 (20.0) 0.647
Residing in an area known to have a high
prevalence of community-acquired MRSA
37 (21.4) 30 (19.4) 7 (38.9) 0.070 14 (12.3) 14 (12.8) 0 1.000
Smoking statusc
Current smoker 33 (19.3) 29 (19.0) 4 (22.2) 0.412 33 (29.2) 30 (27.8) 3 (60.0) 0.377
Ex-smoker 66 (38.6) 57 (37.3) 9 (50.0) 19 (16.8) 19 (17.6) 0
Nonsmoker 72 (42.1) 67 (43.8) 5 (27.8) 61 (54.0) 59 (54.6) 2 (40.0)
Data missing 2 2 0 1 1 0
On hemodialysisc 6 (3.5) 6 (3.9) 0 1.000 0 0 0
Currently in acute renal failurec 16 (9.2) 15 (9.7) 1 (5.6) 1.000 6 (5.3) 6 (5.5) 0 1.000
Patient operative statusc
Nonoperative 132 (76.3) 118 (76.1) 14 (77.8) 0.372 70 (61.4) 66 (60.6) 4 (80.0) 1.000
Emergency postoperative 27 (15.6) 23 (14.8) 4 (22.2) 29 (25.4) 28 (25.7) 1 (20.0)
Elective postoperative 14 (8.1) 14 (9.0) 0 15 (13.2) 15 (13.8) 0
With history of severe organ system insufficiency/
immunocompromisedc
10 (5.8) 9 (5.8) 1 (5.6) 1.000 4 (3.5) 4 (3.7) 0 1.000
Diabetes and cardiac comorbidityc 118 (68.2) 104 (67.1) 14 (77.8) 0.432 58 (50.9) 55 (50.5) 3 (60.0) 1.000
Respiratory insufficiency/failurec 105 (60.7) 93 (60.0) 12 (66.7) 0.799 76 (66.7) 72 (66.1) 4 (80.0) 0.663
On a ventilator at the time of randomizationc 76 (43.9) 71 (45.8) 5 (27.8) 0.210 49 (43.0) 49 (45.0) 0 0.069
Baseline bacteremia with S. aureusc 13 (7.5) 10 (6.5) 3 (16.7) 0.139 8 (7.0) 8 (7.3) 0 1.000
In ICUe at baselinec 85 (49.1) 77 (49.7) 8 (44.4) 0.805 61 (53.5) 60 (55.0) 1 (20.0) 0.182
Mean body mass index (SD) (kg/m2)b 25.9 (6.72) 25.9 (6.92) 25.6 (4.73) 0.819 26.8 (6.26) 26.9 (6.23) 24.8 (7.29) 0.467
Mean total APACHE II score (SD)b 15.5 (5.99) 15.6 (5.95) 14.5 (6.44) 0.449 13.4 (5.85) 13.4 (5.82) 12.4 (7.09) 0.697
a Excluding the P value columns, values shown are numbers (percentages) of patients unless otherwise indicated.
b Assessed by two-sample t test.
c Assessed by Fisher’s exact test (for 2-by-2 tables) or the Fisher-Freeman-Halton test (for tables larger than 2 by 2).
d “Other” includes Argentina, Australia, Brazil, Chile, China, India, Israel, Lebanon, Malaysia, Peru, Philippines, South Africa, South Korea, Taiwan, and Thailand.
e ICU, intensive care unit.
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TABLE 2 Outcome for patients with Staphylococcus aureus hospital-acquired pneumonia stratified by clinically relevant characteristics
Parameter
Value by PVL status
MRSA MSSA
Cure rate (%)
P valuea
Cure rate (%)
P valuea
pvl negative
(n 155)
pvl positive
(n 18)
pvl negative
(n 109)
pvl positive
(n 5)
Demographic characteristics
Age 0.524 0.153
65 yr 50/54 (92.6) 7/8 (87.5) 55/63 (87.3) 3/5 (60.0)
65 yr 73/101 (72.3) 9/10 (90.0) 38/46 (82.6) 0/0
Sex 0.362 0.178
Male 59/80 (73.8) 12/13 (92.3) 54/63 (85.7) 1/3 (33.3)
Female 64/75 (85.3) 4/5 (80.0) 39/46 (84.8) 2/2 (100.0)
Region of enrollment 0.349 0.215
Europe 37/45 (82.2) 3/3 (100.0) 44/49 (89.8) 0/1 (0.0)
North America 26/35 (74.3) 9/11 (81.8) 20/25 (80.0) 1/2 (50.0)
Otherb 60/75 (80.0) 4/4 (100.0) 29/35 (82.9) 2/2 (100.0)
Prior antimicrobial therapy 0.531 0.167
Yes 92/116 (79.3) 10/11 (90.9) 37/42 (88.1) 2/4 (50.0)
No 31/39 (79.5) 6/7 (85.7) 56/67 (83.6) 1/1 (100)
MRSA risk factor 0.531 0.145
Yes 122/153 (79.7) 16/18 (88.9) 81/97 (83.5) 2/4 (50.0)
No 1/2 (50.0) 0/0 12/12 (100) 1/1 (100.0)
Hospitalization within previous 6 months 0.532 0.193
Yes 80/100 (80.0) 8/9 (88.9) 35/40 (87.5) 1/1 (100.0)
No 43/55 (78.2) 8/9 (88.9) 58/69 (84.1) 2/4 (50.0)
Antibiotic treatment within prior 3 months 0.531 0.175
Yes 84/108 (77.8) 9/10 (90.0) 31/36 (86.1) 0/1 (0.0)
No 39/47 (83.0) 7/8 (87.5) 62/73 (84.9) 3/4 (75.0)
Chronic illness 0.531 0.197
Yes 101/130 (77.7) 13/14 (92.9) 53/63 (84.1) 2/4 (50.0)
No 22/25 (88.0) 3/4 (75.0) 40/46 (87.0) 1/1 (100.0)
Prior infection with MRSA 0.533 0.165
Yes 15/17 (88.2) 1/2 (50.0) 1/2 (50.0) 0/0
No 108/138 (78.3) 15/16 (93.8) 92/107 (86.0) 3/5 (60.0)
Admission from a nursing home or long term care facility 0.533 0.206
Yes 23/30 (76.7) 3/4 (75.0) 10/10 (100.0) 0/0
No 100/125 (80.0) 13/14 (92.9) 83/99 (83.8) 3/5 (60.0)
Surgical procedure during current hospital stay 0.532 0.137
Yes 33/42 (78.6) 3/4 (75.0) 35/44 (79.5) 0/1 (0.0)
No 90/113 (79.6) 13/14 (92.9) 58/65 (89.2) 3/4 (75.0)
Residing in an area known to have a high prevalence of
community-acquired MRSA
0.356 0.143
Yes 21/30 (70.0) 5/7 (71.4) 10/14 (71.4) 0/0
No 102/125 (81.6) 11/11 (100.0) 83/95 (87.4) 3/5 (60.0)
Smoking status 0.530 0.182
Nonsmoker 54/67 (80.6) 5/5 (100.0) 52/59 (88.1) 2/2 (100.0)
Current or ex-smoker 69/86 (80.2) 11/13 (84.6) 41/49 (83.7) 1/3 (33.3)
On hemodialysis 0.531 0.176
Yes 5/6 (83.3) 0/0 0/0 0/0
No 118/149 (79.2) 16/18 (88.9) 93/109 (85.3) 3/5 (60.0)
(Continued on following page)
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other virulence genes and clinical outcome. The results of these
comparisons are demonstrated in Table 3. After adjustment for
multiple comparisons (data not shown) to control the false dis-
covery rate for the family of all the tests, no significant associations
between clinical outcome and presence or absence of any of the 30
other putative virulence genes were detected for patients with ei-
ther MRSA or MSSA HAP (Table 3).
Alpha-hemolysin production and outcome of S. aureus
HAP. Because alpha-hemolysin has also been identified as a viru-
lence factor in S. aureus pneumonia (2, 3) and might be acting in
concert with PVL to augment pulmonary inflammation (4), we
quantified alpha-hemolysin activity in the culture supernatant of
all 23 pvl-constitutive isolates, as well as 23 randomly selected
pvl-negative S. aureus isolates matched according to methicillin
susceptibility. There was no evidence that clinical cure rates were
related to high or low levels of alpha-hemolysin production in
vitro (Table 4).
Effect of agr dysfunction in clinical outcome. Because previ-
ous reports have suggested that dysfunction of the agr locus could
result in attenuation in virulence (14, 39, 40, 46, 48), we evaluated
agr function in all 286 S. aureus HAP isolates by using a delta-
hemolysin activity/phenotyping assay. Of the 286 isolates, 191
(66.8%) exhibited a functional agr by the delta-hemolysin pheno-
typing assay (MRSA, 54.1% [93/172];MSSA, 86.0% [98/114]).No
significant association was identified between agr function and
clinical outcome in either MRSA or MSSA HAP (Fig. 2).
MLST and clinical outcome. To consider the possibility that
pvl presence could serve as a surrogate marker for a more virulent
S. aureus clone, we used MLST to genotype all pvl-positive S. au-
reus isolates and a collection of randomly selected pvl-negative S.
TABLE 2 (Continued)
Parameter
Value by PVL status
MRSA MSSA
Cure rate (%)
P valuea
Cure rate (%)
P valuea
pvl negative
(n 155)
pvl positive
(n 18)
pvl negative
(n 109)
pvl positive
(n 5)
Currently in acute renal failure 0.532 0.193
Yes 12/15 (80.0) 1/1 (100.0) 6/6 (100.0) 0/0
No 111/140 (79.3) 15/17 (88.2) 87/103 (84.5) 3/5 (60.0)
Patient was nonoperative 0.532 0.150
Yes 95/118 (80.5) 13/14 (92.9) 58/66 (87.9) 3/4 (75.0)
No 28/37 (75.7) 3/4 (75.0) 35/43 (81.4) 0/1 (0.0)
History of severe organ system insufficiency/
immunocompromised
0.530 0.187
Yes 5/9 (55.6) 1/1 (100.0) 4/4 (100.0) 0/0
No 118/146 (80.8) 15/17 (88.2) 89/105 (84.8) 3/5 (60.0)
Diabetes and cardiac comorbidity 0.361 0.203
Yes 76/104 (73.1) 13/14 (92.9) 43/55 (78.2) 1/3 (33.3)
No 47/51 (92.2) 3/4 (75.0) 50/54 (92.6) 2/2 (100.0)
Respiratory insufficiency/failure 0.532 0.196
Yes 71/93 (76.3) 10/12 (83.3) 60/72 (83.3) 2/4 (50.0)
No 52/62 (83.9) 6/6 (100.0) 33/37 (89.2) 1/1 (100.0)
On a ventilator at the time of randomization 0.530 0.137
Yes 54/71 (76.1) 4/5 (80.0) 40/49 (81.6) 0/0
No 69/84 (82.1) 12/13 (92.3) 53/60 (88.3) 3/5 (60.0)
Baseline bacteremia with S. aureus 0.532 0.181
Yes 7/10 (70.0) 3/3 (100.0) 7/8 (87.5) 0/0
No 116/145 (80.0) 13/15 (86.7) 86/101 (85.1) 3/5 (60.0)
In ICUc at baseline 0.532 0.124
Yes 59/77 (76.6) 7/8 (87.5) 48/60 (80.0) 1/1 (100.0)
No 64/78 (82.1) 9/10 (90.0) 45/49 (91.8) 2/4 (50.0)
APACHE II score 0.525 0.184
0-13 points 59/68 (86.8) 8/8 (100.0) 55/61 (90.2) 2/3 (66.7)
14-19 points 41/51 (80.4) 4/6 (66.7) 26/30 (86.7) 1/1 (100.0)
20 points 23/36 (63.9) 4/4 (100.0) 12/18 (66.7) 0/1 (0.0)
a Two-sided P value from an exact test of the null hypothesis of no association between clinical outcome and pvl status, stratifying on the covariate.
b “Other” includes Argentina, Australia, Brazil, Chile, China, India, Israel, Lebanon, Malaysia, Peru, Philippines, South Africa, South Korea, Taiwan, and Thailand.
c ICU, intensive care unit.
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aureus isolates matched 1:1 (23 pvl-positive and 23 pvl-negative S.
aureus isolates) (Table 5). Most pvl-positive S. aureus isolates be-
longed to CC8 (12/23 [52.2%]), whereas the most common CC
among pvl-negative isolates was CC5 (11/23 [47.8%]). No clones
were significantly associated with worse clinical outcome.
DISCUSSION
The impact of pvl on the severity of S. aureus pneumonia is un-
known. Using S. aureus isolates from a large collection of contem-
porary, geographically diverse, clinically well-characterized HAP
patients, the current investigation foundno evidence that pvlpres-
ence is associated with a more severe clinical course. This finding
has several key implications.
The results of the present study demonstrate that the simple
presence of pvl is not the primary outcome determinant in S. au-
reus HAP. Our finding is consistent with that of a recent study
from Peyrani et al. (33). While an important hypothesis-
generating observation, the Peyrani study was limited by its rela-
tively small sample size, retrospective study design, limitation to
MRSA-infected patients, geographically limited enrollment (4
U.S. centers), failure to confirm PVL production, and failure to
consider the potential impact of other bacterial virulence charac-
teristics. The current study overcomes all of these limitations to
provide compelling evidence that factors other than the simple
presence of PVL are the primary determinant of outcome in pa-
tients with HAP due to S. aureus. Our study findings persisted
after adjusting for multiple patient and bacterial characteristics
and are consistent with several other lines of evidence. First, the
results of this study are consistent with three previous reports by
our group that show a similar lack of association between pvl
TABLE 3 Association between putative virulence genes and clinical outcome among patients with hospital-acquired pneumonia due to methicillin-
resistant or methicillin-sensitive Staphylococcus aureus
Gene
MRSA (n 173) MSSA (n 114)
No. (%) of patients
with genotype
Cure rate (no./total [%]) with:
P valuea
No. (%) of
patients with
genotype
Cure rate (no./total [%]) with:
P valueaGene absent Gene present Gene absent Gene present
Adhesin genes
fnbA 173/173 (100.0) 0/0 139/173 (80.3) 114/114 (100.0) 0/0 96/114 (84.2)
clfA 142/173 (82.1) 24/31 (77.4) 115/142 (81.0) 0.625 114/114 (100.0) 0/0 96/114 (84.2)
clfB 125/173 (72.3) 39/48 (81.3) 100/125 (80.0) 1.000 43/114 (37.7) 62/71 (87.3) 34/43 (79.1) 0.292
cna 75/173 (43.4) 79/98 (80.6) 60/75 (80.0) 1.000 52/114 (45.6) 48/62 (77.4) 48/52 (92.3) 0.039
spa 173/173 (100.0) 0/0 139/173 (80.3) 114/114 (100.0) 0/0 96/114 (84.2)
sdrC 157/173 (90.8) 15/16 (93.8) 124/157 (79.0) 0.202 49/114 (43.0) 56/65 (86.2) 40/49 (81.6) 0.607
sdrD 154/173 (89.0) 16/19 (84.2) 123/154 (79.9) 1.000 74/114 (64.9) 35/40 (87.5) 61/74 (82.4) 0.595
sdrE 148/173 (85.5) 19/25 (76.0) 120/148 (81.1) 0.588 68/114 (59.6) 38/46 (82.6) 58/68 (85.3) 0.795
bbp 160/173 (92.5) 9/13 (69.2) 130/160 (81.3) 0.288 107/114 (93.9) 4/7 (57.1) 92/107 (86.0) 0.077
ebpS 173/173 (100.0) 0/0 139/173 (80.3) 114/114 (100.0) 0/0 96/114 (84.2)
map-eap 58/173 (33.5) 92/115 (80.0) 47/58 (81.0) 1.000 14/114 (12.3) 85/100 (85.0) 11/14 (78.6) 0.462
fnbB 120/173 (69.4) 47/53 (88.7) 92/120 (76.7) 0.096 36/114 (31.6) 66/78 (84.6) 30/36 (83.3) 1.000
Toxin genes
pvl 18/173 (10.4) 123/155 (79.4) 16/18 (88.9) 0.532 5/114 (4.4) 93/109 (85.3) 3/5 (60.0) 0.176
eta 115/173 (66.5) 51/58 (87.9) 88/115 (76.5) 0.104 63/114 (55.3) 44/51 (86.3) 52/63 (82.5) 0.617
etb 11/173 (6.4) 130/162 (80.2) 9/11 (81.8) 1.000 10/114 (8.8) 89/104 (85.6) 7/10 (70.0) 0.193
tst 80/173 (46.2) 74/93 (79.6) 65/80 (81.3) 0.849 47/114 (41.2) 60/67 (89.6) 36/47 (76.6) 0.072
sea 104/173 (60.1) 53/69 (76.8) 86/104 (82.7) 0.435 59/114 (51.8) 45/55 (81.8) 51/59 (86.4) 0.610
seb 4/173 (2.3) 135/169 (79.9) 4/4 (100.0) 1.000 7/114 (6.1) 90/107 (84.1) 6/7 (85.7) 1.000
sec 36/173 (20.8) 109/137 (79.6) 30/36 (83.3) 0.814 32/114 (28.1) 67/82 (81.7) 29/32 (90.6) 0.391
sed 63/173 (36.4) 88/110 (80.0) 51/63 (81.0) 1.000 24/114 (21.1) 76/90 (84.4) 20/24 (83.3) 1.000
see 56/173 (32.4) 92/117 (78.6) 47/56 (83.9) 0.540 19/114 (16.7) 80/95 (84.2) 16/19 (84.2) 1.000
seg 109/173 (63.0) 51/64 (79.7) 88/109 (80.7) 1.000 60/114 (52.6) 45/54 (83.3) 51/60 (85.0) 1.000
seh 8/173 (4.6) 131/165 (79.4) 8/8 (100.0) 0.358 16/114 (14.0) 83/98 (84.7) 13/16 (81.3) 0.716
sei 160/173 (92.5) 11/13 (84.6) 128/160 (80.0) 1.000 99/114 (86.8) 11/15 (73.3) 85/99 (85.9) 0.252
hlg 172/173 (99.4) 1/1 (100.0) 138/172 (80.2) 1.000 108/114 (94.7) 5/6 (83.3) 91/108 (84.3) 1.000
Others
efb 173/173 (100.0) 0/0 139/173 (80.3) 114/114 (100.0) 0/0 96/114 (84.2)
icaA 170/173 (98.3) 3/3 (100.0) 136/170 (80.0) 1.000 113/114 (99.1) 1/1 (100.0) 95/113 (84.1) 1.000
chp 128/173 (74.0) 37/45 (82.2) 102/128 (79.7) 0.829 91/114 (79.8) 19/23 (82.6) 77/91 (84.6) 0.758
V8 160/173 (92.5) 11/13 (84.6) 128/160 (80.0) 1.000 85/114 (74.6) 26/29 (89.7) 70/85 (82.4) 0.556
Agr group II vs.
all others
71/173 (41.0) 85/102 (83.3) 54/71 (76.1) 0.249 34/114 (29.8) 67/80 (83.8) 29/34 (85.3) 1.000
SCC type II
(4/non-4)
29/173 (16.8) 114/144 (79.2) 25/29 (86.2) 0.454 0/114 (0.0) 96/114 (84.2) 0/0
a Two-sided P value from Fisher’s exact test of the null hypothesis of no association between clinical outcome and the presence/absence of the putative virulence genes. After
adjustment for multiple comparisons to control the false discovery rate for the family of all the tests, there was no significant difference between clinical outcome and PVL status.
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presence and higher likelihood of worse patient outcome in com-
plicated skin and skin structure infections (1, 5, 44). In all of those
studies, pvl presence was not associated with more severe infec-
tion, and in two of these studies (1, 5), pvl presence was actually
associated with a significantly higher cure rate. Second, levels of
PVL production do not appear to correlate with severity of infec-
tion (18). By enzyme-linked immunosorbent assay (ELISA), S.
aureus strains from severe infections like necrotizing pneumonia
were not the hyperproducers of PVL toxin compared to those
associated with comparatively minor infections. Third, severe ne-
crotizing pneumonia has been associated with pvl-negative
community-acquired MRSA (CA-MRSA) strains (43). Collec-
tively, these findings support the notion that factors other than the
simple presence of pvl are responsible for influencing severity in a
variety of S. aureus infections (32), including HAP.
Alpha-hemolysin is an important virulence factor in pneumo-
nia (2, 3). Because it may act in concert with PVL to induce pul-
monary inflammation (4), we considered its additive impact on
clinical severity of S. aureus HAP. No significant differences in
cure rates were identified among the high alpha-lysin producers
within pvl-positive or pvl-negative isolates. These findings suggest
that our understanding of the pathogenesis of S. aureus pneumo-
nia remains incomplete and that the determinants of infection
severity are far more complex than the presence or absence of a
few virulence characteristics.
Approximately one-third of the HAP isolates in the present
studywere delta-hemolysin deficient, suggesting that agr dysfunc-
tion did not reduce the capacity of S. aureus to cause invasive
infection. The expression of virulence factors, including toxins
and adhesins, in S. aureus is controlled by a global polycistronic
regulatory locus, agr. This regulatory network encodes the
quorum-sensing system that coordinates the expression of se-
creted and cell-associated virulence factors in a cell-density-
dependent manner (29). Because delta-hemolysin is encoded by
hld within the agr locus and is derived from the translation of
RNAIII, the effector of agr regulon, its production is a marker of
TABLE 4 Clinical outcome versus alpha-lysin production among patients with Staphylococcus aureus hospital-acquired pneumoniab
S. aureus type and
amt of alpha-lysina
PVL PVL
No. of isolates No. of isolates
Cure Failure Total Cure Failure Total
MRSA
High 4 (80.0) 1 (20.0) 5 1 (100.0) 0 1
Low 12 (92.3) 1 (7.7) 13 13 (76.5) 4 (23.5) 17
Total 16 (88.9) 2 (11.1) 18 14 (77.8) 4 (22.2) 18
MSSA
High 2 (100.0) 0 2 1 (50.0) 1 (50.0) 2
Low 1 (33.3) 2 (66.7) 3 1 (33.3) 2 (66.7) 3
Total 3 (60.0) 2 (40.0) 5 2 (40.0) 3 (60.0) 5
a High,10 HU/ml; low,10 HU/ml.
b The P value for MRSA and MSSA pooled was 1.00, as calculated by using an exact Monte Carlo Cochran-Mantel-Haenszel test, with stratification on methicillin susceptibility
(MRSA or MSSA).
FIG 1 Cure rates among patients due to methicillin-resistant (MRSA) or
methicillin-sensitive (MSSA) Staphylococcus aureus hospital-acquired pneu-
monia according to presence or absence of pvl.
FIG 2 Cure rates among patients due to methicillin-resistant (MRSA) or
methicillin-sensitive (MSSA) Staphylococcus aureus hospital-acquired pneu-
monia according to delta-lysin (DEL) production.
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agr function (36). Loss of agr function has been linked to attenu-
ated virulence (48) and has global effects on bacterial phenotypes
(14, 40, 46) and increased mortality among S. aureus bacteremia
patients (39). However, we found no evidence in the current in-
vestigation that agr dysfunction is associated with the outcome
of HAP.
The prevalence of pvl in S. aureus varies widely among different
infection types (7, 8, 21, 23–27, 33, 37, 38, 41, 45). Less than 10%
of the S. aureus HAP isolates in this study contained pvl. This
relatively low prevalence stands in sharp contrast to trends seen in
soft tissue infections (1, 45) as well as in a pneumonia study in
children (6).
Our study had several limitations. First, our study focused by
design on patients with S. aureus HAP, while most prior reports
that link PVL with pneumonia involved community-acquired S.
aureus necrotizing pneumonia (15, 16). Thus, our findings would
not apply to community-acquired S. aureus necrotizing pneumo-
nia. This is an important distinction because of the prior health
status of the infected individuals, i.e., those with community-
acquired S. aureus necrotizing pneumonia were typically other-
wise healthy, whereas patients with S. aureusHAP had risk factors
for infection (and were thus highly susceptible to infection). Pre-
viously existing susceptibility of the HAP patients to infection
could in part explain the finding that there was no significant
association between clinical outcome and presence or absence of
putative virulence genes (Table 3). Such molecules might simply
be unnecessary to cause infection in these immunocompromised
patients. Second, the proportion of isolates harboring and ex-
pressing PVL was low (10%) and thus limited the statistical
power of finding associations. Although wemust remain cautious
in the conclusions drawn from the present study, the fact that
other investigators (33) have recently reported the same result
strengthens its generalizability. Third, we evaluated alpha-
hemolysin levels in vitro, and it remains unclear whether in vitro
activity is a reflection of relative toxin production in vivo.
Study strengths include the fact that we have utilized one of the
largest cohorts of patients with HAP, including large subgroups
with S. aureus and MRSA. Therefore, although proportionally
there were few pvl-positive isolates, this is likely to be one of the
largest cohorts of patients with staphylococcal HAP to allow any
comparison between pvl-positive and pvl-negative groups. Be-
sides the larger size of the cohort, the other strengths of this inves-
tigation included its contemporary nature, multinational design,
and detailed clinical and laboratory data. Finally, confirmation of
pvl genotyping data by PVL Western blotting further strengthens
the study findings.
In summary, this study provides evidence that PVL presence is
not the primary determinant of outcome among patients with S.
aureus HAP. This finding suggests that clinical outcome may be
more significantly influenced by the presence of several bacterial
virulence factors acting in concert than by the mere presence of
pvl. Alternately, currently unrecognized or recently discovered
virulence factors (e.g., phenol soluble modulins [31] or the novel
bicomponent leukotoxin LukGH [47]) as well as the host genetic
factors may also contribute to clinical outcome. The discovery of
an exact virulence determinant needs further elucidation using
appropriate in vivo models and using a collection of widely dis-
tributed well characterized strains. We anticipate future studies
will combine clinical data with not only the presence/absence of
any genotype but also technologies such as RNASeq to determine
the relationships between pathogen transcriptome and clinical
outcomes.
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